Paradoxical effects of rapamycin on experimental house dust mite-induced asthma

• Published in: PloS one 2012-05, Vol.7 (5), p.e33984-e33984
• Main Authors: Fredriksson, Karin, Fielhaber, Jill A, Lam, Jonathan K, Yao, Xianglan, Meyer, Katharine S, Keeran, Karen J, Zywicke, Gayle J, Qu, Xuan, Yu, Zu-Xi, Moss, Joel, Kristof, Arnold S, Levine, Stewart J
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Antigens; Asthma; Asthma - drug therapy; Asthma - etiology; Asthma - immunology; Asthma - metabolism; Biocompatibility; Biology; Bronchoalveolar Lavage Fluid - chemistry; Cell growth; Critical care; Dendritic cells; Dust; Female; Heart; House dust; Hyperplasia; Hypersensitivity; Immune response; Inflammation; Inflammation - drug therapy; Inflammation - etiology; Inflammation - immunology; Inflammation - metabolism; Inhibition; Laboratories; Lung - drug effects; Lung - immunology; Lung - metabolism; Lymph nodes; Lymphocytes; Lymphocytes T; Medical research; Medicine; Medicine, Experimental; Mice; Mice, Inbred BALB C; Mites; Pathogenesis; Phosphatase; Phosphorylation; Phosphorylation - drug effects; Pyroglyphidae - immunology; Rapamycin; Respiratory tract; Respiratory tract diseases; Reverse Transcriptase Polymerase Chain Reaction; Rodents; Signal Transduction - drug effects; Signal Transduction - genetics; Signaling; Sirolimus - therapeutic use; T cells; TOR protein; TOR Serine-Threonine Kinases - genetics; TOR Serine-Threonine Kinases - metabolism; Toxicity; Transplants & implants
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0033984

The mammalian target of rapamycin (mTOR) modulates immune responses and cellular proliferation. The objective of this study was to assess whether inhibition of mTOR with rapamycin modifies disease severity in two experimental murine models of house dust mite (HDM)-induced asthma. In an induction model, rapamycin was administered to BALB/c mice coincident with nasal HDM challenges for 3 weeks. In a treatment model, nasal HDM challenges were performed for 6 weeks and rapamycin treatment was administered during weeks 4 through 6. In the induction model, rapamycin significantly attenuated airway inflammation, airway hyperreactivity (AHR) and goblet cell hyperplasia. In contrast, treatment of established HDM-induced asthma with rapamycin exacerbated AHR and airway inflammation, whereas goblet cell hyperplasia was not modified. Phosphorylation of the S6 ribosomal protein, which is downstream of mTORC1, was increased after 3 weeks, but not 6 weeks of HDM-challenge. Rapamycin reduced S6 phosphorylation in HDM-challenged mice in both the induction and treatment models. Thus, the paradoxical effects of rapamycin on asthma severity paralleled the activation of mTOR signaling. Lastly, mediastinal lymph node re-stimulation experiments showed that treatment of rapamycin-naive T cells with ex vivo rapamycin decreased antigen-specific Th2 cytokine production, whereas prior exposure to in vivo rapamycin rendered T cells refractory to the suppressive effects of ex vivo rapamycin. We conclude that rapamycin had paradoxical effects on the pathogenesis of experimental HDM-induced asthma. Thus, consistent with the context-dependent effects of rapamycin on inflammation, the timing of mTOR inhibition may be an important determinant of efficacy and toxicity in HDM-induced asthma.